Literature DB >> 1873917

Response of urinary angiotensin to challenges of the renin-angiotensin system.

P Boer1, P F Vos, H A Koomans, A J Rabelink, J J Beutler, E J Dorhout Mees.   

Abstract

Angiotensin has an intrarenal action which may not parallel its action in the general circulation. We investigated whether the urinary excretion rates of angiotensin I and II (UV-AI, UV-AII) can be used as a marker of renal production. We therefore measured UV-AI, UV-AII, plasma angiotensin I and II (PAI, PAII), and plasma renin activity (PRA) in healthy subjects under conditions influencing the renin-angiotensin system: captopril injection (n = 7), enalapril treatment (n = 9), furosemide infusion on high and low sodium intake (n = 6), indomethacin treatment (n = 8), and head-out water immersion (three sodium intakes). After captopril (acute) and enalapril (chronic), PAI and PRA increased, PAII decreased, but neither UV-AI nor UV-AII changed. During furosemide infusion, PAI, PAII, PRA, as well as UV-AI and UV-AII increased. During indomethacin treatment, PAI, PAII, and PRA decreased, whereas UV-AI and UV-AII did not change consistently. Sodium restriction increased PAI, PAII, and PRA, but did not alter UV-AI and UV-AII. Head-out immersion decreased PAI, PAII, and PRA, but did not change UV-AI and UV-AII. The relative constancy of the urinary AI and AII excretion rates makes it doubtful whether urinary angiotensins reflect changes of renal angiotensin production.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873917     DOI: 10.1016/0009-8981(91)90111-o

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

1.  Do alterations of endogenous angiotensin II levels regulate erythropoietin production in humans?

Authors:  S Freudenthaler; P Benöhr; A Grenz; T Selzer; T Schmidt; K Mörike; H Osswald; C H Gleiter
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.